Towards this end, we found that genetic inhibition of adipose triglyceride lipase (ATGL) specifically in adipocytes is sufficient to prevent the development of obesity-related HFpEF, and that pharmacological inhibition of ATGL using atglistatin effectively treats established disease. This evidence concerns the gene PNPLA2 and obesity due to melanocortin 4 receptor deficiency.